Genomic Vision Société Anonyme (0QT4.L)
| Previous close | 0.1771 |
| Open | 0.1000 |
| Bid | 0.0000 x N/A |
| Ask | 0.0000 x N/A |
| Day's range | 0.1000 - 0.1000 |
| 52-week range | 0.1000 - 0.1000 |
| Volume | |
| Avg. volume | N/A |
| Market cap | N/A |
| Beta (5Y monthly) | 0.00 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.1190 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Business Wire
Genomic Vision: First-half 2022 Results
BAGNEUX, France, September 29, 2022--Regulatory News: Genomic Vision (the "Company" - FR0011799907 – GV), a biotechnology company that develops tools and services dedicated to the analysis and control of changes in the genome, today announces its half-year financial results to June 30th, 20221. The H1 financial report is available in the Investors section of Genomic Vision’s website.
- Business Wire
Genomic Vision Announces the Issuance of the 1st Tranche of Convertible Notes With Warrants (OCABSA) for €2 Million, as Part of the Financing Line Concluded With Winance for a Maximum Amount of €30 Million
BAGNEUX, France, September 06, 2022--Regulatory News: Genomic Vision (the "Company" - FR0011799907 – GV) (Paris:GV), a biotechnology company that develops tools and services dedicated to the analysis and control of changes in the genome, today announces the issuance of the first tranche of convertible notes with equity warrants attached (OCABSA) for a total net amount of €1.920 million.
- Business Wire
Genomic Vision: Financial Information for the First Half of 2022
BAGNEUX, France, July 22, 2022--Regulatory News: Genomic Vision (FR0011799907 - GV, PEA-PME eligible) (Paris:GV), a biotechnology company developing tools and services dedicated to the analysis and control of genome modifications, today announced its first half revenues and cash position at June 30, 2022.
